Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla Diagnostics

This article was originally published in The Tan Sheet

Executive Summary

Acquires domestic and international marketing rights from an undisclosed source for a rapid home pregnancy test that has been available in the U.S. for the past two years, the company reports Jan. 6. Initial marketing efforts will focus on sub-Saharan Africa and other international markets, where the company currently markets HIV and tuberculosis diagnostic tests. La Jolla plans to sell the product in the U.S. at a "substantially lower price" than the current $8 average, but a launch is not expected for several months
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel